Stock Quote
Johnson & Johnson (JNJ) (NYSE Arca)
$62.69
23 Nov 2009
+0.61%
$62.69
--
13,867,906
$63.10
$62.42
$62.74
$46.25
0.56
12,467,960
JNJ
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Weldon, William | Chairman of the Board, Chief Executive Officer | 29,392,200 |
| Caruso, Dominic | Chief Financial Officer, Vice President - Finance | 3,921,030 |
| Goggins, Colleen | Worldwide Chairman - Consumer Group | 8,490,270 |
Profile
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. Johnson & Johnson has more than 250 operating companies. The Company operates in three segments. The Consumer segment includes a range of products used in the baby care,... Full Description
Company Address
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick NJ 08933
P: +1732.5240400
F: +1732.2140332
One Johnson & Johnson Plaza
New Brunswick NJ 08933
P: +1732.5240400
F: +1732.2140332
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Novartis AG | CHF55.65 | +0.50 |
| The Procter & Gamble Company | $62.73 | +0.93 |
| Pfizer Inc. | $18.53 | +0.17 |
| JNJ | Industry | |
|---|---|---|
| P/E(TTM) | 13.70 | 3.57 |
| P/S(TTM) | 2.86 | 0.57 |
| ROI(TTM) | 18.61 | 1.86 |
| ROE(TTM) | 26.58 | 2.51 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | 1.27 |
| EPS Est. (Current Year) | 4.58 |
| Total Revenue | $15,081.00M |
| Net Income | $3,345.00M |
| EPS | $1.20 |
